DE60112050D1 - Rekombinantes influenza a virus - Google Patents

Rekombinantes influenza a virus

Info

Publication number
DE60112050D1
DE60112050D1 DE60112050T DE60112050T DE60112050D1 DE 60112050 D1 DE60112050 D1 DE 60112050D1 DE 60112050 T DE60112050 T DE 60112050T DE 60112050 T DE60112050 T DE 60112050T DE 60112050 D1 DE60112050 D1 DE 60112050D1
Authority
DE
Germany
Prior art keywords
gene
virus
relates
influenza
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112050T
Other languages
English (en)
Other versions
DE60112050T2 (de
Inventor
Boris Ferko
Andre Egorov
Regina Voglauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Application granted granted Critical
Publication of DE60112050D1 publication Critical patent/DE60112050D1/de
Publication of DE60112050T2 publication Critical patent/DE60112050T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE60112050T 2000-03-02 2001-03-02 Rekombinantes influenza a virus Expired - Lifetime DE60112050T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00104338 2000-03-02
EP00104338 2000-03-02
PCT/EP2001/002392 WO2001064860A2 (en) 2000-03-02 2001-03-02 Recombinant influenza a viruses

Publications (2)

Publication Number Publication Date
DE60112050D1 true DE60112050D1 (de) 2005-08-25
DE60112050T2 DE60112050T2 (de) 2006-04-27

Family

ID=8168006

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112050T Expired - Lifetime DE60112050T2 (de) 2000-03-02 2001-03-02 Rekombinantes influenza a virus

Country Status (7)

Country Link
US (1) US6800288B2 (de)
EP (1) EP1259629B1 (de)
AT (1) ATE299943T1 (de)
AU (2) AU5035201A (de)
DE (1) DE60112050T2 (de)
RU (1) RU2280690C2 (de)
WO (1) WO2001064860A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1085904B1 (de) 1998-06-12 2012-11-28 Mount Sinai School of Medicine Abgeschwächte minussträngige viren mit veränderter interferon antagonistischen aktivität zur verwendung in impfstoffen und medikamenten
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
WO2004111249A2 (en) * 2003-06-13 2004-12-23 Polymun Scientific Immunbiologische Forschung Gmbh Protein constructs containing caspase recognition sites
EP2581093B1 (de) 2003-06-16 2015-03-18 MedImmune, LLC Influenza-Hämagglutinin- und Neuraminidase-Varianten
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CA2551489C (en) 2003-12-23 2013-09-03 Gregory Duke Multi plasmid system for the production of influenza virus
WO2005116260A2 (en) 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2497492B1 (de) 2004-06-01 2018-08-08 Icahn School of Medicine at Mount Sinai Genetisch veränderter Schweineinfluenzavirus und Verwendungen damit
WO2006013367A2 (en) * 2004-08-04 2006-02-09 Medical Research Council Chimeric heamaglutinin proteins and uses thereof
US8137676B2 (en) * 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
EP2471552B1 (de) 2005-03-08 2015-05-06 MedImmune, LLC Reassortierte Influenza-Viren
AT502275B8 (de) * 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
CA2631812C (en) 2005-12-02 2023-08-29 Peter Palese Chimeric viruses presenting non-native surface proteins and uses thereof
WO2008133701A1 (en) * 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
KR101559184B1 (ko) * 2006-08-09 2015-10-13 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
CA2690627C (en) 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
WO2008157583A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
EP2048237A1 (de) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replikationsdefizienter Influenza-Virus zur Expression heterologer Sequenzen
SG154418A1 (en) * 2008-01-31 2009-08-28 Sumitomo Chemical Co Granular composition and production thereof
RU2523587C2 (ru) * 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
WO2010093537A2 (en) 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
KR101426407B1 (ko) * 2011-11-10 2014-08-07 서울대학교산학협력단 고생산성, 고면역원성, 및 무병원성 인플루엔자 바이러스 제작용 재조합 발현 벡터
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
SI3063273T1 (sl) 2013-10-28 2020-03-31 Blue Sky Vaccines Gmbh Vektor virusa gripe za viroterapijo
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201791907A1 (ru) 2015-02-26 2018-02-28 Бёрингер Ингельхайм Ветмедика Гмбх Бивалентная вакцина против вируса свиного гриппа
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
RU2660562C2 (ru) * 2016-03-30 2018-07-06 Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ" Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
EA037571B1 (ru) * 2015-11-06 2021-04-15 Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ" Аттенуированный вирус гриппа а, аттенуированный грипозный вектор, фармацевтическая композиция и их применение для профилактики или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
RU2706191C1 (ru) * 2018-12-28 2019-11-14 Общество с ограниченной ответственностью "Нанолек" Поливалентная вакцина против гриппа
RU2706544C1 (ru) * 2018-12-28 2019-11-19 Общество с ограниченной ответственностью "Нанолек" Концентрат вакцины от гриппа и способ его получения
RU2701953C1 (ru) * 2018-12-28 2019-10-02 Общество с ограниченной ответственностью "Нанолек" Способ получения поливалентной вакцины от гриппа
RU2701959C1 (ru) * 2018-12-28 2019-10-02 Общество с ограниченной ответственностью "Нанолек" Способ контроля получения продукта вакцина от гриппа
CN113481171B (zh) * 2021-06-21 2022-10-18 武汉大学 一种携带hiv-1基因的重组流感病毒株及其制备方法与应用
US20240033347A1 (en) 2022-07-08 2024-02-01 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
CA2334857C (en) * 1998-06-12 2012-03-20 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
EP1085904B1 (de) 1998-06-12 2012-11-28 Mount Sinai School of Medicine Abgeschwächte minussträngige viren mit veränderter interferon antagonistischen aktivität zur verwendung in impfstoffen und medikamenten

Also Published As

Publication number Publication date
ATE299943T1 (de) 2005-08-15
EP1259629A2 (de) 2002-11-27
RU2280690C2 (ru) 2006-07-27
DE60112050T2 (de) 2006-04-27
US6800288B2 (en) 2004-10-05
WO2001064860A3 (en) 2002-02-21
AU5035201A (en) 2001-09-12
US20030147916A1 (en) 2003-08-07
AU2001250352B2 (en) 2006-01-12
WO2001064860A2 (en) 2001-09-07
EP1259629B1 (de) 2005-07-20
RU2002126205A (ru) 2004-03-10

Similar Documents

Publication Publication Date Title
ATE299943T1 (de) Rekombinantes influenza a virus
DK1086207T3 (da) Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
CY1120558T1 (el) Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου
HRP20041085B1 (hr) Inhibitori hepatitis c virusa
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
NO20025627L (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
WO2006133911A3 (en) Hepatitis c virus nucleic acid vaccine
DK1441761T3 (da) Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
CY1107776T1 (el) Νεα παραγωγα ολιγο-νουκλεοτιδιων για στοχευμενη αναστολη της εκφρασης γονιδιων
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
CY1113786T1 (el) Εξασθενημενοι ιοι πολιομυελιτιδας
HUP0300727A2 (hu) Nukleinsav-konstrukciók, ezekkel transzformált vaszkuláris sejtek, ezeket a konstrukciókat hasznosító gyógyászati kompozíciók, és eljárások angiogenezis indukálásához
BR9915703B1 (pt) mutante do vìrus da raiva recombinante, e, vacina anti-rábica atenuada viva.
ATE332967T1 (de) Antisense oligonukleotide zur hemmung der expression der integrin alphav untereinheit
WO2004009764A3 (en) Methods and compositions concerning altered yellow fever virus strains
Pekcan Cyclic behaviour of Adapazarı clayey silts
HUP0203268A2 (hu) Önhasadó RNS-szekvenciák és alkalmazásuk fehérjeszintézis szabályozására
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
DK1676586T3 (da) Fremgangsmåde til adskillelse af rotavirusvarianter samt levende, svækket rotavirusvaccine
Rubin pH Probes.
李莹莹 A Tentative Study of Two Chinese Versions of David Copperfield
FI893346A (fi) Icke-reverterande rna-virus.
ES1050317Y (es) Antirrobo y control permanente e individual de obras de arte.
Fauzi Study on the structure and cleavage reaction mechanism of Human Hepatitis Delta Virus (HDV) ribozyme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition